{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:39:12Z","timestamp":1792103952641,"version":"4.4.0"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["8037"],"award-info":[{"award-number":["8037"]}],"id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973389"],"award-info":[{"award-number":["81973389"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008376","name":"HUS Helsinki University Hospital","doi-asserted-by":"publisher","award":["TYH2021304"],"award-info":[{"award-number":["TYH2021304"]}],"id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008376","name":"HUS Helsinki University Hospital","doi-asserted-by":"publisher","award":["TYH2019300"],"award-info":[{"award-number":["TYH2019300"]}],"id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202006100163"],"award-info":[{"award-number":["202006100163"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["325667"],"award-info":[{"award-number":["325667"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejps.2024.106884","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T13:33:15Z","timestamp":1725024795000},"page":"106884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["In vitro assessment of inhibitory effects of kinase inhibitors on CYP2C9, 3A and 1A2: Prediction of drug-drug interaction risk with warfarin and direct oral anticoagulants"],"prefix":"10.1016","volume":"203","author":[{"given":"Shasha","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-No\u00eblle","family":"Paludetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Kurkela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helin\u00e4","family":"Kahma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Neuvonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9577-2788","authenticated-orcid":false,"given":"Janne T.","family":"Backman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2024.106884_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2012.07.006","article-title":"Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects","volume":"34,","author":"Abbas","year":"2012","journal-title":"Clin. Ther."},{"key":"10.1016\/j.ejps.2024.106884_bib0002","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1124\/dmd.112.046888","article-title":"Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans","volume":"40","author":"Bathala","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106884_bib0003","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1021\/acs.molpharmaceut.7b01108","article-title":"Role of hepatic organic anion transporter 2 in the pharmacokinetics of R- and S-warfarin: in vitro studies and mechanistic evaluation","volume":"15","author":"Bi","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2024.106884_bib0004","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00280-010-1507-6","article-title":"A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)","volume":"67","author":"Bullock","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106884_bib0005","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1097\/CAD.0000000000000099","article-title":"Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer","volume":"25","author":"Calvert","year":"2014","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejps.2024.106884_bib0006","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/jcph.1036","article-title":"Physiologically based pharmacokinetic modeling to evaluate the systemic exposure of gefitinib in CYP2D6 ultrarapid metabolizers and extensive metabolizers","volume":"58","author":"Chen","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106884_bib0007","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1124\/dmd.122.000876","article-title":"Pharmacokinetic modeling of warfarin \u0406 - model-based analysis of warfarin enantiomers with a target mediated drug disposition model reveals CYP2C9 genotype-dependent drug-drug interactions of S-warfarin","volume":"50","author":"Cheng","year":"2022","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106884_bib0009","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1111\/bcp.15158","article-title":"Application of a physiologically based pharmacokinetic model of rivaroxaban to prospective simulations of drug-drug-disease interactions with protein kinase inhibitors in cancer-associated venous thromboembolism","volume":"88","author":"Cheong","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106884_bib0010","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.3109\/10428194.2013.876631","article-title":"Drug-drug interaction between bosutinib and warfarin","volume":"55","author":"Chintakuntlawar","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejps.2024.106884_bib0011","first-page":"935","article-title":"Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2024.106884_bib0012","series-title":"Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis","first-page":"270","article-title":"Modes of reversible inhibition","author":"Copeland","year":"2000"},{"key":"10.1016\/j.ejps.2024.106884_bib0013","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/jcph.752","article-title":"Pharmacokinetic properties of nintedanib in healthy volunteers and patients with advanced cancer","volume":"56","author":"Dallinger","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106884_bib0014","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00008571-200305000-00002","article-title":"Pharmacogenetics of oral anticoagulants","volume":"13","author":"Daly","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.ejps.2024.106884_bib0015","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s10637-013-9962-7","article-title":"Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study","volume":"31","author":"Eisen","year":"2013","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejps.2024.106884_bib0016","unstructured":"EMA, 2022. ICH Guideline M12 on drug interaction studies. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-ich-guideline-m12-drug-interaction-studies-step-2b_en.pdf (Accessed on 28\/9\/2023)."},{"key":"10.1016\/j.ejps.2024.106884_bib0017","unstructured":"EMA, 2017. Masipro (masitinib): EPAR-Refusal public assessment report. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/masipro-epar-refusal-public-assessment-report_en.pdf (Accessed on 9\/4\/2023)."},{"key":"10.1016\/j.ejps.2024.106884_bib0018","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.clpt.2004.04.003","article-title":"Time response of cytochrome P450 1A2 activity on cessation of heavy smoking","volume":"76","author":"Faber","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106884_bib0019","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1124\/dmd.108.026252","article-title":"Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction","volume":"37","author":"Fahmi","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106884_bib0020","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejps.2024.106884_bib0021","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13046-023-02623-2","article-title":"Targeting IGF1R signaling enhances the sensitivity of cisplatin by inhibiting proline and arginine metabolism in oesophageal squamous cell carcinoma under hypoxia","volume":"42","author":"Fang","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2024.106884_bib0022","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2125.2009.03572.x","article-title":"Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction","volume":"69","author":"Fang","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106884_bib0023","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejps.2024.106884_bib0024","unstructured":"FDA, 2020. Clinical drug interaction studies-cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. https:\/\/www.fda.gov\/media\/134581\/download (Accessed on 5\/2\/2022)."},{"key":"10.1016\/j.ejps.2024.106884_bib0025","unstructured":"FDA, 2014. Ofev (nintedanib) Drug Label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205832s000lbl.pdf (Accessed on 14\/8\/2023)."},{"key":"10.1016\/j.ejps.2024.106884_bib0026","unstructured":"FDA, 2013a. Mekinist (trametinib) clinical pharmacology and biopharmaceutics reviews. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204114Orig1s000ClinPharmR.pdf (Accessed on 14\/6\/2024)."},{"key":"10.1016\/j.ejps.2024.106884_bib0027","unstructured":"FDA, 2013b. Mekinist (trametinib) drug label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204114s000lbl.pdf (Accessed on 14\/8\/2023)."},{"key":"10.1016\/j.ejps.2024.106884_bib0028","unstructured":"FDA, 2012a. Cabometyx (cabozantinib) drug label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208692s000lbl.pdf (Accessed 5\/2\/2022)."},{"key":"10.1016\/j.ejps.2024.106884_bib0029","unstructured":"FDA, 2012b. Inlyta (axitinib) drug label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202324lbl.pdf (Accessed 5\/2\/2022)."},{"key":"10.1016\/j.ejps.2024.106884_bib0030","unstructured":"FDA, 2012c. Stivarga (regorafenib) clinical pharmacology and biopharmaceutics review. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/203085Orig1s000ClinPharmR.pdf (Accessed 5\/2\/2022)."},{"key":"10.1016\/j.ejps.2024.106884_bib0031","unstructured":"FDA, 2012d Inlyta (axitinib) pharmacology reviews. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202324Orig1s000PharmR.pdf (Accessed on 5\/8\/2022)."},{"key":"10.1016\/j.ejps.2024.106884_bib0032","unstructured":"FDA, 2012e. Stivarga (regorafenib) product label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/203085lbl.pdf (Accessed 5\/2\/2022)."},{"key":"10.1016\/j.ejps.2024.106884_bib0033","unstructured":"FDA, 2009. Votrient (pazopanib) drug label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022465lbl.pdf (Accessed on 5\/2\/2022)."},{"key":"10.1016\/j.ejps.2024.106884_bib0034","unstructured":"FDA, 2004. Tarceva (erlotinib) drug label. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021743s025lbl.pdf (Accessed on 14\/8\/2023)."},{"key":"10.1016\/j.ejps.2024.106884_bib0035","unstructured":"FDA, 2003. Iressa clinical pharmacology and biopharmaceutics reviews. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/21-399_IRESSA_Clinr.pdf (Accessed on 5\/8\/2022)."},{"key":"10.1016\/j.ejps.2024.106884_bib0036","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1111\/j.1476-5381.2011.01732.x","article-title":"Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates","volume":"165","author":"Filppula","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106884_bib0037","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/bcpt.13088","article-title":"In vitro screening of six protein kinase inhibitors for time-dependent inhibition of CYP2C8 and CYP3A4: possible implications with regard to drug-drug interactions","volume":"123","author":"Filppula","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejps.2024.106884_bib0038","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1124\/dmd.114.057695","article-title":"In vitro assessment of time-dependent inhibitory effects on CYP2C8 and CYP3A activity by fourteen protein kinase inhibitors","volume":"42","author":"Filppula","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106884_bib0039","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/jcph.813","article-title":"CYP2C9 genotype-dependent warfarin pharmacokinetics: impact of CYP2C9 genotype on R- and S-warfarin and their oxidative metabolites","volume":"57","author":"Flora","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106884_bib0040","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/hep.510240407","article-title":"Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin","volume":"24","author":"Fromm","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.ejps.2024.106884_bib0041","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.phrs.2018.07.016","article-title":"Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)","volume":"135","author":"Gelosa","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejps.2024.106884_bib0042","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.tips.2022.04.006","article-title":"Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules","volume":"43","author":"Goebel","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejps.2024.106884_bib0043","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1009820","article-title":"Machine learning-driven identification of drugs inhibiting cytochrome P450 2C9","volume":"18","author":"Goldwaser","year":"2022","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.ejps.2024.106884_bib0044","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40262-022-01204-4","article-title":"Can mechanistic static models for drug-drug interactions support regulatory filing for study waivers and label recommendations?","volume":"62","author":"Gomez-Mantilla","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2024.106884_bib0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0009-9236(03)00118-8","article-title":"Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice","volume":"74","author":"Greenblatt","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106884_bib0046","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/bdd.1771","article-title":"Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice","volume":"33","author":"Grillo","year":"2012","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.ejps.2024.106884_bib0047","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1124\/dmd.109.026716","article-title":"The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America","volume":"37","author":"Grimm","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106884_bib0048","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00280-018-3545-4","article-title":"Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model","volume":"81","author":"Gruber","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106884_bib0049","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.bcp.2014.01.016","article-title":"The multikinase inhibitor axitinib is a potent inhibitor of human CYP1A2","volume":"88","author":"Gu","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106884_bib0050","article-title":"IGF1R contributes to cell proliferation in ALK-mutated neuroblastoma with preference for activating the PI3K-AKT signaling pathway","volume":"15, 4252","author":"Guan","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejps.2024.106884_bib0051","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1007\/s00204-020-02936-7","article-title":"Inhibition and induction of CYP enzymes in humans: an update","volume":"94","author":"Hakkola","year":"2020","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.ejps.2024.106884_bib0052","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/138920009788897975","article-title":"Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects","volume":"10","author":"Hartmann","year":"2009","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.ejps.2024.106884_bib0053","first-page":"1733","article-title":"Effects of seven tyrosine kinase inhibitors on the anticoagulation activity of warfarin","volume":"46","author":"Hiraide","year":"2019","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/j.ejps.2024.106884_bib0054","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1177\/1078155218801061","article-title":"Drug interactions between tyrosine kinase inhibitors (gefitinib and erlotinib) and warfarin: assessment of international normalized ratio elevation characteristics and in vitro CYP2C9 activity","volume":"25","author":"Hiraide","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.ejps.2024.106884_bib0055","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.resinv.2020.11.007","article-title":"Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism","volume":"59","author":"Hotta","year":"2021","journal-title":"Respir. Investig."},{"key":"10.1016\/j.ejps.2024.106884_bib0056","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/cncr.24927","article-title":"Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors","volume":"116","author":"Johnson","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejps.2024.106884_bib0057","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0022-3565(24)35013-X","article-title":"Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation","volume":"290","author":"Jones","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2024.106884_bib0058","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1158\/1078-0432.CCR-14-0265","article-title":"Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors","volume":"21","author":"Jones","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejps.2024.106884_bib0059","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1124\/dmd.106.009944","article-title":"Metabolism and disposition of vatalanib (PTK787\/ZK-222584) in cancer patients","volume":"34","author":"Jost","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106884_bib0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2021.105810","article-title":"An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes - application to establishing CYP2C8 inhibitor selectivity","volume":"162","author":"Kahma","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2024.106884_bib0061","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1124\/dmd.118.085498","article-title":"Critical differences between enzyme sources in sensitivity to detect time-dependent inactivation of CYP2C8","volume":"47","author":"Kahma","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106884_bib0062","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0163-7258(96)00140-4","article-title":"Human P450 metabolism of warfarin","volume":"73","author":"Kaminsky","year":"1997","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106884_bib0063","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1023\/A:1007509324428","article-title":"Quantitative prediction of in vivo drug-drug interactions from in vitro data based on physiological pharmacokinetics: use of maximum unbound concentration of inhibitor at the inlet to the liver","volume":"17","author":"Kanamitsu","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2024.106884_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120349","article-title":"Quantitative analysis of an impact of P-glycoprotein on edoxaban's disposition using a human physiologically based pharmacokinetic (PBPK) model","volume":"597","author":"Kato","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2024.106884_bib0065","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1007\/s11095-012-0724-6","article-title":"Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction","volume":"29","author":"Kenny","year":"2012","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2024.106884_bib0066","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2024.106884_bib0067","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1080\/10428194.2021.1876864","article-title":"A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed\/refractory multiple myeloma","volume":"62","author":"Khan","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ejps.2024.106884_bib0068","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clpt.2004.08.009","article-title":"Clinical consequences of cytochrome P450 2C9 polymorphisms","volume":"77","author":"Kirchheiner","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106884_bib0069","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40780-016-0050-y","article-title":"Elevated prothrombin time\/international normalized ratio associated with concurrent administration of regorafenib and warfarin in a patient with advanced colorectal cancer","volume":"2","author":"Kitade","year":"2016","journal-title":"J. Pharm. Health Care Sci."},{"key":"10.1016\/j.ejps.2024.106884_bib0070","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1016\/S0021-9258(18)50153-8","article-title":"Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase","volume":"237","author":"Kitz","year":"1962","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2024.106884_bib0071","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2125.2011.04051.x","article-title":"The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors","volume":"73","author":"Lane","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106884_bib0072","article-title":"Prognostic and predictive utility of GPD1L in human hepatocellular carcinoma","volume":"24, 13113","author":"Leung","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2024.106884_bib0073","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.1038\/s41598-023-33213-z","article-title":"The combined signatures of the tumour microenvironment and nucleotide metabolism-related genes provide a prognostic and therapeutic biomarker for gastric cancer","volume":"13","author":"Liu","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2024.106884_bib0074","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1111\/bcp.14621","article-title":"Drug interaction of ningetinib and gefitinib involving CYP1A1 and efflux transporters in non-small cell lung cancer patients","volume":"87","author":"Liu","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106884_bib0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0287126","article-title":"Automation, live-cell imaging, and endpoint cell viability for prostate cancer drug screens","volume":"18","author":"Lyles","year":"2023","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejps.2024.106884_bib0076","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1200\/JCO.2009.22.3032","article-title":"Cancer, clots and consensus: new understanding of an old problem","volume":"27","author":"Lyman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2024.106884_bib0077","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2125.2012.04335.x","article-title":"The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype","volume":"75","author":"Maddison","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106884_bib0078","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/cncr.22816","article-title":"Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer","volume":"110","author":"Milton","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejps.2024.106884_bib0079","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.953098","article-title":"Combinatorial delivery of CPI444 and vatalanib loaded on PEGylated graphene oxide as an effective nanoformulation to target glioblastoma multiforme: in vitro evaluation","volume":"12","author":"Mishra","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejps.2024.106884_bib0080","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00280-010-1299-8","article-title":"Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer","volume":"66","author":"Mitry","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106884_bib0081","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.2146\/ajhp080436","article-title":"Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin","volume":"66","author":"Moretti","year":"2009","journal-title":"Am. J. Health. Syst. Pharm."},{"key":"10.1016\/j.ejps.2024.106884_bib0082","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.4155\/fmc.09.89","article-title":"Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor","volume":"1","author":"Mulvihill","year":"2009","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejps.2024.106884_bib0083","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106884_bib0084","series-title":"Drug-Drug Interactions","first-page":"271","article-title":"In Vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs (reaction phenotyping) with emphasis on cytochrome P450","author":"Ogilvie","year":"2008"},{"key":"10.1016\/j.ejps.2024.106884_bib0085","doi-asserted-by":"crossref","first-page":"16416","DOI":"10.1002\/cam4.6282","article-title":"Inhibition of VEGFR2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinoma","volume":"12","author":"Onda","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.ejps.2024.106884_bib0086","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/jjco\/hyi122","article-title":"Drug interaction between gefitinib and warfarin","volume":"35","author":"Onoda","year":"2005","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.ejps.2024.106884_bib0087","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1124\/dmd.119.086496","article-title":"Regulatory recommendations for calculating the unbound maximum hepatic inlet concentration: a complicated story with a surprising and happy ending","volume":"47","author":"Parkinson","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106884_bib0088","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1124\/dmd.111.038596","article-title":"An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes","volume":"39","author":"Parkinson","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106884_bib0089","doi-asserted-by":"crossref","unstructured":"Pavic, M., Hermine, O., Spaeth, D., 2021. LBA02-11masitinib plus docetaxel as first-line treatment of metastatic castrate refractory prostate cancer: results from study AB12003. J. Urol. 206, e1179. https:\/\/doi.org\/10.1097\/JU.0000000000002149.11.","DOI":"10.1097\/JU.0000000000002149.11"},{"key":"10.1016\/j.ejps.2024.106884_bib0090","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620936325","article-title":"Drug-drug interactions of 257 antineoplastic and supportive care agents with 7 anticoagulants: a comprehensive review of interactions and mechanisms","volume":"26","author":"Peixoto de Miranda","year":"2020","journal-title":"Clin. Appl. Thromb. Hemost."},{"key":"10.1016\/j.ejps.2024.106884_bib0091","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s40495-020-00212-x","article-title":"Utilization of physiologically based pharmacokinetic modeling in clinical pharmacology and therapeutics: an overview","volume":"6","author":"Perry","year":"2020","journal-title":"Curr. Pharmacol. Rep."},{"key":"10.1016\/j.ejps.2024.106884_bib0092","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00280-016-2999-5","article-title":"Mass balance, pharmacokinetics, and metabolism of linsitinib in cancer patients","volume":"77","author":"Poondru","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106884_bib0093","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10822-010-9335-7","article-title":"Warfarin: history, tautomerism and activity","volume":"24","author":"Porter","year":"2010","journal-title":"J. Comput. Aided Mol. Des."},{"key":"10.1016\/j.ejps.2024.106884_bib0094","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/1078155216677853","article-title":"Supratherapeutic INR resulting from the initiation of warfarin in a patient receiving axitinib","volume":"24","author":"Primeaux","year":"2018","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.ejps.2024.106884_bib0095","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejps.2011.04.008","article-title":"Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover","volume":"43","author":"Rowland Yeo","year":"2011","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2024.106884_bib0096","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cpt.917","article-title":"Harnessing meta-analysis to refine an oncology patient population for physiology-based pharmacokinetic modeling of drugs","volume":"103","author":"Schwenger","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106884_bib0097","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1067\/mcp.2002.129321","article-title":"Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance","volume":"72","author":"Scordo","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106884_bib0098","unstructured":"Simcyp, 2016a. Simcyp prediction tools-fumic. https:\/\/members.simcyp.com\/account\/tools\/fumic\/(Accessed on 18\/5\/2022)."},{"key":"10.1016\/j.ejps.2024.106884_bib0099","unstructured":"Simcyp, 2016b. Simcyp prediction tools - blood to plasma partition ratio (B\/P) https:\/\/members.simcyp.com\/account\/tools\/BP\/(Accessed on 15\/5\/2022)."},{"key":"10.1016\/j.ejps.2024.106884_bib0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.cnur.2020.10.003","article-title":"Fat-soluble vitamins","volume":"56","author":"Stevens","year":"2021","journal-title":"Nurs. Clin. North Am."},{"key":"10.1016\/j.ejps.2024.106884_bib0101","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00008571-199710000-00004","article-title":"Genetic association between sensitivity to warfarin and expression of CYP2C9*3","volume":"7","author":"Steward","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.ejps.2024.106884_bib0102","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/clpt.1987.104","article-title":"Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects","volume":"42","author":"Toon","year":"1987","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106884_bib0103","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00280-010-1318-9","article-title":"Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors","volume":"67","author":"Traynor","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106884_bib0104","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1124\/dmd.121.000497","article-title":"Static and dynamic projections of drug-drug interactions caused by cytochrome P450 3A time-dependent inhibitors measured in human liver microsomes and hepatocytes","volume":"49","author":"Tseng","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106884_bib0105","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","article-title":"Clinical pharmacokinetics of tyrosine kinase inhibitors","volume":"35","author":"Van Erp","year":"2009","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ejps.2024.106884_bib0106","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/clpt.2013.187","article-title":"Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug","volume":"95","author":"Vieira","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2024.106884_bib0107","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/14656566.2018.1459566","article-title":"Masitinib in treatment of pancreatic cancer","volume":"19","author":"Waheed","year":"2018","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejps.2024.106884_bib0108","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/bcp.12427","article-title":"Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)","volume":"78","author":"Wang","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106884_bib0109","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1124\/dmd.120.000131","article-title":"Evaluation of the disconnect between hepatocyte and microsome intrinsic clearance and in vitro in vivo extrapolation performance","volume":"48","author":"Williamson","year":"2020","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106884_bib0110","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.drudis.2015.07.008","article-title":"Small-molecule kinase inhibitors: an analysis of FDA-approved drugs","volume":"21","author":"Wu","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2024.106884_bib0111","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1111\/bcp.14743","article-title":"Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug-drug interactions, renal impairment and paediatric populations","volume":"87","author":"Xu","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106884_bib0112","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-007-0494-8","article-title":"Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors","volume":"61","author":"Yamamoto","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106884_bib0113","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1124\/dmd.106.013359","article-title":"Misuse of the well-stirred model of hepatic drug clearance","volume":"35","author":"Yang","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106884_bib0114","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0090-9556(25)06865-5","article-title":"Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe","volume":"23","author":"Zhang","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2024.106884_bib0115","article-title":"Risk assessment and molecular mechanism study of drug-drug interactions between rivaroxaban and tyrosine kinase inhibitors mediated by CYP2J2\/3A4 and BCRP\/P-gp","volume":"13","author":"Zhao","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejps.2024.106884_bib0116","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.2147\/DDDT.S237301","article-title":"Effects of apatinib on the pharmacokinetics of nifedipine and warfarin in patients with advanced solid tumors","volume":"14","author":"Zhu","year":"2020","journal-title":"Drug Des. Dev. Ther."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724001969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098724001969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:17:26Z","timestamp":1778775446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098724001969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":115,"alternative-id":["S0928098724001969"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106884","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro assessment of inhibitory effects of kinase inhibitors on CYP2C9, 3A and 1A2: Prediction of drug-drug interaction risk with warfarin and direct oral anticoagulants","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2024.106884","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106884"}}